HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.50 | 15.30 | 0.17% |
| CAC 40 | 7,745.69 | 52.53 | -0.67% |
| DAX 40 | 24,074.09 | 233.71 | -0.96% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,011.43 | 1.56 | -0.02% |
| HKSE | 25,130.03 | 135.89 | 0.54% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
| NZX 50 Index | 12,833.74 | 127.77 | -0.99% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
| SSE Composite Index | 3,581.86 | 22.07 | 0.62% |